NEW YORK (GenomeWeb) – 23andMe today announced an agreement with drug developer Reset Therapeutics to study the genetics of the circadian clock.
The goal of the collaboration is to develop drug targets for therapeutics that will restore the body's 24-hour physiological rhythms, Reset said in a statement.
Through this collaboration, 23andMe will provide Reset scientists with de-identified, aggregated data from more than 650,000 customers who have consented for their genomic information to be a part of scientific research.
"Working with 23andMe, we will amplify our R&D capabilities by incorporating a large-scale human genetics element in our research platform in a way that wasn't possible," Reset President and CEO Ross Bersot said in a statement. "With this collaboration we will be able to more efficiently and effectively drive our clinical programs."
The Reset research team will study the clock genes associated with chronotype, sleep, insulin resistance, stress response, and related pathophysiology to identify novel circadian drug targets.
Financial details of the agreement were not disclosed.